Megan Lynch/LinkedIn
Jun 16, 2026, 16:17
Megan Lynch: Thrilled to Join AstraZeneca
Megan Lynch, Global Product Leader, Cell Therapy Enterprise at AstraZeneca, shared a post on LinkedIn:
“I’m thrilled to share that I’m joining AstraZeneca as a Global Product Leader, Cell Therapy Enterprise.
Cell therapy is transforming how we treat patients across hem/onc, autoimmune, and rare disease.
Getting innovative medicines to patients and providers has always been my north star and I can’t wait to dig in.
Thank you to Margie Li, Margaret DiGuardo, Carsten Linnemann, Craig Maxwell, and Eva Piqué for your partnership throughout this process — I’m looking forward to what we’ll build together.
Here’s to what’s next.”

Stay updated with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery